Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 5506 AL 5520

Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease

Prvulovic D, Bokde AL, Faltraco F, Hampel H.

Prog Neurobiol. 2011 Dec;95(4):557-69. doi: 10.1016/j.pneurobio.2011.05.008. Epub 2011 Jun 22.

Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment

Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H.

Curr Pharm Des. 2011;17(25):2594-602. doi: 10.2174/138161211797416039.

Alzheimer's disease

Brody H.

Nature. 2011 Jul 13;475(7355):S1. doi: 10.1038/475S1a.

[Application of mass spectrometry-based chromatographic technologies in the diagnosis of Alzheimer's disease]

Wang D, Xin G, Shi Z, Chen J, Li P.

Se Pu. 2011 Apr;29(4):293-7. doi: 10.3724/sp.j.1123.2011.00293.

FDG-PET imaging, EEG and sleep phenotypes as translational biomarkers for research in Alzheimer's disease

Platt B, Welch A, Riedel G.

Biochem Soc Trans. 2011 Aug;39(4):874-80. doi: 10.1042/BST0390874.

Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications

Ferreira LK, Busatto GF.

Clinics (Sao Paulo). 2011;66 Suppl 1(Suppl 1):19-24. doi: 10.1590/s1807-59322011001300003.

Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use

Frisoni GB, Winblad B, O'Brien JT.

Int Psychogeriatr. 2011 Oct;23(8):1191-6. doi: 10.1017/S1041610211001220. Epub 2011 Aug 4.

Utility of imaging for nutritional intervention studies in Alzheimer's disease

de Wilde MC, Kamphuis PJ, Sijben JW, Scheltens P.

Eur J Pharmacol. 2011 Sep;668 Suppl 1:S59-69. doi: 10.1016/j.ejphar.2011.07.011. Epub 2011 Jul 27.

Neurochemical dementia diagnostics in Alzheimer's disease: where are we now and where are we going?

Lewczuk P, Kornhuber J.

Expert Rev Proteomics. 2011 Aug;8(4):447-58. doi: 10.1586/epr.11.37.

CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease

Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.

J Alzheimers Dis. 2011;27(2):377-84. doi: 10.3233/JAD-2011-110482.

New diagnostic criteria for Alzheimer's disease

Zetterberg H.

Biomark Med. 2011 Aug;5(4):407-9. doi: 10.2217/bmm.11.46.

Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease

Lista S, Emanuele E.

Biomark Med. 2011 Aug;5(4):411-3. doi: 10.2217/bmm.11.50.

Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease

Parnetti L, Chiasserini D.

Biomark Med. 2011 Aug;5(4):479-84. doi: 10.2217/bmm.11.48.

Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond

Diniz BS, Teixeira AL.

Neuromolecular Med. 2011 Dec;13(4):217-22. doi: 10.1007/s12017-011-8154-x. Epub 2011 Sep 7.

[Dementia: progress in diagnosis and treatment; Topics; V. Recent topics; 1. Biomarkers for Alzheimer's disease and other dementia]

Tokuda T.

Nihon Naika Gakkai Zasshi. 2011 Aug 10;100(8):2177-86. doi: 10.2169/naika.100.2177.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias